Ryan Martins Net Worth

The estimated Net Worth of Ryan Martins is at least $823 Thousand dollars as of 4 April 2023. Mr. Martins owns over 8,721 units of 89bio Inc stock worth over $434,518 and over the last 5 years he sold ETNB stock worth over $388,773. In addition, he makes $0 as Chief Financial Officer at 89bio Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Martins ETNB stock SEC Form 4 insiders trading

Ryan has made over 7 trades of the 89bio Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 8,721 units of ETNB stock worth $130,379 on 4 April 2023.

The largest trade he's ever made was exercising 10,000 units of 89bio Inc stock on 19 April 2021 worth over $31,100. On average, Ryan trades about 1,491 units every 29 days since 2020. As of 4 April 2023 he still owns at least 53,578 units of 89bio Inc stock.

You can see the complete history of Mr. Martins stock trades at the bottom of the page.

Ryan Martins biography

Ryan Martins serves as Chief Financial Officer of the Company. Prior to joining our company, Mr. Martins was Chief Financial Officer at Revolution Medicines, Inc., from March 2018 to October 2018, where he was responsible for all aspects of the finance function including financial accounting, capital planning, audit, tax and investor relations. Before Revolution Medicines, Mr. Martins was Vice President and Head of Corporate Strategy and Investor Relations at Ultragenyx Pharmaceutical, Inc., from September 2015 to March 2018, where he was responsible for strategic planning, capital raising, investor relations and assisting business development. Prior to Ultragenyx, Mr. Martins spent nearly 10 years as a biotechnology analyst at Jefferies, Lazard, and Barclays/Lehman Brothers after holding operating roles at Chiron Corporation from 2001 to 2006.

How old is Ryan Martins?

Ryan Martins is 43, he's been the Chief Financial Officer of 89bio Inc since 2019. There are 15 older and 1 younger executives at 89bio Inc. The oldest executive at 89bio Inc is Michael Hayden, 68, who is the Independent Director.

What's Ryan Martins's mailing address?

Ryan's mailing address filed with the SEC is C/O 89BIO, INC., 142 SANSOME STREET, 2ND FLOOR, SAN FRANCISCO, CA, 94104.

Insiders trading at 89bio Inc

Over the last 5 years, insiders at 89bio Inc have traded over $17,267,666 worth of 89bio Inc stock and bought 14,519,952 units worth $208,678,684 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Ra ..., and Advisors Llc Orbi Med Capit.... On average, 89bio Inc executives and independent directors trade stock every 28 days with the average trade being worth of $2,197,340. The most recent stock trade was executed by Rohan Palekar on 1 April 2024, trading 52,718 units of ETNB stock currently worth $575,153.

What does 89bio Inc do?

89bio, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. its lead product candidate is bio89-100, a glycopegylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. the company also intends to develop bio89-100 for the treatment of severe hypertriglyceridemia. 89bio, inc. was founded in 2018 and is based in san francisco, california.

Complete history of Mr. Martins stock trades at 89bio Inc

89bio Inc executives and stock owners

89bio Inc executives and other stock owners filed with the SEC include:

• Rohan Palekar,
  Chief Executive Officer, Director
• Rohan Palekar,
  CEO & Director
• Hank Mansbach,
  Chief Medical Officer
• Dr. Harry Mansbach M.D.,
  Chief Medical Officer
• Dr. Hank Mansbach M.D.,
  Chief Medical Officer
• Quoc Le-Nguyen,
  Chief Technical Operations Officer and Head of Quality
• Quoc Le-Nguyen,
  Chief Technical Operations Officer & Head of Quality
• Ram Waisbourd,
  Chief Operating Officer and Chief Business Officer
• Michael Hayden,
  Independent Director
• Anat Naschitz,
  Independent Director
• Gregory Grunberg,
  Independent Director
• Derek DiRocco,
  Independent Director
• Ryan Martins,
  Chief Financial Officer
• Steven Altschuler,
  Independent Chairman of the Board of Director
• Yun Bai,
  VP & Head of CMC
• Amanda Hill,
  VP of People & Culture
• Melissa Abel,
  VP of Commercial Strategy & Communication
• Shiva K. Natarajan,
  VP of Fin. & Principal Accounting Officer
• Ram Waisbourd,
  COO & Chief Bus. Officer
• Ryan Stephen Martins,
  Chief Financial Officer
• Charles Mc Wherter,
  
• Tomer Pontifax (Israel) V, ...,
  
• Capital Management, L.P.Ra ...,
  
• Advisors Llc Orbi Med Capit...,
  
• Capital Partners Iii, Llc L...,
  
• Kathleen Laporte,
  
• Edward Morrow Iii Atkinson,
  
• Capital Management, L.P.Ra ...,
  
• Harry H Mansbach,
  Chief Medical Officer
• Lota S. Zoth,
  
• Martin Babler,
  
• Francis Willard Sarena,
  Chief Operating Officer